Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180171 | 0.83 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL2322538 | 0.83 | TRPA1 (0.39) | CYP2C19ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL2329877 | 0.81 | TP53 (0.40) | TRPV4ALDH1A1LMNAHSD17B10TP53 | |
| SCHEMBL1550345 | 0.80 | TSHR (0.33) | TRPV4CYP3A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL2329024 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGDHSD17B10NPC1 | |
| SCHEMBL1550333 | 0.75 | MAPK1 (0.58) | ALDH1A1LMNAHPGDNPC1RAB9A | |
| SCHEMBL1406667 | 0.74 | KMT2A (0.49) | TRPV4CYP2C19ALDH1A1LMNAHPGD | |
| SCHEMBL574545 | 0.73 | RAB9A (0.48) | CYP3A4CYP2C19ALDH1A1LMNAHPGD | |
| SCHEMBL2325459 | 0.73 | SMN1; SMN2 (0.48) | ALDH1A1LMNAHPGDHSD17B10NPC1 | |
| SCHEMBL2326711 | 0.72 | ALDH1A1 (0.33) | CYP2C19ALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501940-B2 | Tetrahydrocinnoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2313375-A1 | TETRAHYDROCINNOLINES AS 11 BETA HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-La Roche AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2010006940-A1 | TETRAHYDROCINNOLINES AS 11 BETA HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016325-A1 | TETRAHYDROCINNOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016325-A1 | TETRAHYDROCINNOLINE DERIVATIVES | CYP27A1, CYP11B1, DHCR7 | TRPV4 3427/4885CYP3A4 114/4885CYP2C19 69/4885 |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | TRPV4 4130/4885CYP3A4 60/4885CYP2C19 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.